Gain slips after early-stage data for Parkinson’s therapy Source: Seekingalpha
Browsing: data
Krystal Biotech’s Jeune reports promising phase 1 data on wrinkles drug Source: (*1*)
Invivyd down 18% despite Pemgarda COVID risk reduction data Source: Seekingalpha
matejmo/E+ by way of Getty Images Patients handled with Invivyd’s (NASDAQ:IVVD) Pemgarda (pemivibart) confirmed an 84% relative risk reduction in symptomatic COVID-19 in comparison with placebo…